Combined estrogen-progestin pill
Drug1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
Other names: OCP
NCT Number: NCT01465022
Objectives
To clarify the relationship between postpartum (2 weeks) use of progestin-only vs. combined oral contraceptive pills and the outcomes of breastfeeding continuation, infant growth, contraceptive method continuation, and pregnancy rates in breastfeeding women. Specific research questions:
1. To determine whether there is a difference in rates of breastfeeding continuation at 2 months and 4 months between postpartum breastfeeding women using progestin-only pills vs. combined pills. 2. To determine whether there is a difference in infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. 3. To determine whether there is a difference in birth control method continuation at 2 months and 4 months between postpartum breastfeeding women using progestin-only pills vs. combined pills.
Hypothesis
Combined oral contraceptive pills, when initiated by postpartum breastfeeding women, will cause a differential in continuation of breastfeeding: 35% continuation in the combined pill group vs. 60% in the progestin-only pill group at 8 weeks.
Looking for future studies?
Notify Me15 year–45 year
Female
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
Other names: OCP
.35 mg norethindrone once a day orally
Other names: POP
Time frame: Baseline to Week 8, Week 8, 2-6 months
Proportion of participants who are continuing to breastfeed from 2 months to 6 months after delivery
Time frame: Baseline to Week 8, Week 8, 2-6 months
Proportion of participants who are continuing to use either combined estrogen-progestin pill or progestin-only pill up to 6 months after delivery
Time frame: Week 2 and Week 8
Comparison of infant length at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.
Time frame: Week 2 and Week 8
Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.
Time frame: Week 2 and Week 8
Comparison of infant growth at 2 weeks and 8 weeks between postpartum breastfeeding women using progestin-only pills vs. combined pills. Inclusion criteria of mother's who are actively breastfeeding.
Looking for future studies?
Notify MeUniversity of New Mexico
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07799545
Behavior, Birth Outcome, Adverse
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05119868
Allergies, Behavior
Naples, Italy
View Trial DetailsNCT07775755
Behavior, Breast Feeding
Tarsus, Mersin, Turkey (Türkiye)
View Trial DetailsNCT07773207
Behavior, Breast Feeding
Elazig, Turkey, Elâzığ, Turkey (Türkiye)
View Trial Details